NCT04362748: Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

NCT04362748
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases or leptomeningeal disease- see trial for details
https://ClinicalTrials.gov/show/NCT04362748

Comments are closed.

Up ↑